Nasdaq GlobeNewswire

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer

Del

Dr. Frédéric Sedel to Transition to CSO

PARIS, July 26, 2018 (GLOBE NEWSWIRE) -- MedDay, a pioneering pharmaceutical company focused on the treatment of nervous system disorders, today announces the appointment of Christian Chavy MBA as Chief Executive Officer, effective 27th August 2018.

Mr. Chavy will succeed Dr. Frédéric Sedel, CEO and Co-Founder of MedDay, who will remain in his existing role until August 27th.  Dr. Sedel will then transition to Chief Scientific Officer and continue to serve on the board of directors.

Commenting on the appointment, Catherine Moukheibir, Chairman of the board, said, "We are thrilled to have Christian take on the role of CEO at this critical time for MedDay as we execute on our confirmatory Phase III clinical trial of MD1003 in progressive MS and make preparations to become a commercial stage company." 

"On behalf of the Board of Directors, I would also like to thank Dr. Frédéric Sedel, our co-founder, who has been instrumental in building MedDay into the company that it is today and has laid the groundwork for a company that ultimately should bring innovative treatments for patients," continued Mrs. Moukheibir. "Under his leadership, MedDay has advanced our lead candidate MD1003 into late stage clinical development, including completion of a successful Phase III trial in progressive MS, and is building a pipeline of promising candidates to treat CNS diseases.  The appointment of Christian Chavy represents a continuation of this strategy. We look forward, also, to further contributions from Frédéric Sedel in his new role as Chief Scientific Officer."

Mr. Christian Chavy commented, "I am honored to be appointed CEO of MedDay.  MD1003, which has a novel mechanism of action and which has already demonstrated strong clinical activity, is positioned to transform the treatment paradigm for progressive multiple sclerosis. We look forward to completing the Phase III trial and see a clear path to approval in the major markets, including U.S. and EU. MedDay is also dedicated to finding effective treatments for severe diseases of the nervous system through our pioneering work of targeting brain metabolism."

Dr. Frédéric Sedel commented, "I am convinced that Christian Chavy has the right skill set and vision to bring MedDay to the next stage. I am very excited with my new role as company CSO which I believe is the area where I can create the most value."

Mr. Chavy is a highly accomplished pharmaceutical executive with experience in Europe and North America. Most recently, he was the CEO of Stallergenes (2014-2016) and Partner at Ares Life Sciences (2010-2014).  His career highlights include 9 years at Actelion Pharmaceuticals (2000-2009) where he was promoted to President of Global Operations, with responsibility over USA, Europe, Japan and rest of the world. Prior to joining Actelion, he was VP, Head of the reproductive health commercial unit at Serono in Geneva and Chairman of Serono's French subsidiary. He also spent five years at Groupe Rhône Poulenc Rorer as its Chairman in Canada, having previously been Chairman and CEO of Rorer France.  Earlier in his career he held roles of increasing responsibility at Bristol-Myers France, SmithKline and French Laboratories, and Merck Sharpe & Dohme.

Mr. Chavy is currently chairman of the board of Ixaltis, a specialty pharmaceutical company developing innovative treatment for genitourinary tract disorders that he founded, and serves on the board of Cerenis. He is a graduate of the Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC) and the Institut de Contrôle de Gestion (ICG).

About MedDay
MedDay is a pioneering pharmaceutical company targeting brain metabolism to treat nervous system disorders. The company was founded in 2011.  The lead product, MD1003 is a formulation of high dose Pharmaceutical grade Biotin (hdPB) developed for progressive multiple sclerosis and other demyelinating diseases. The R&D pipeline also includes MD1103 in autism spectrum disorders and MD1105 in Alzheimer's disease.

MedDay explores brain metabolic pathways through its metabolomics research platform, SPECMET, which supports the discovery of additional pipeline assets. SPECMET screens cerebrospinal fluid (CSF) from patients with various Central Nervous System (CNS) disorders to identify the disrupted metabolic pathways. Compounds that are known to affect these metabolic pathways are then identified and further developed. SPECMET was developed in collaboration with the Commissariat à l'Energie Atomique (CEA) and in March 2017, MedDay acquired the health division of Profilomic SA, an innovative company formed out of the CEA in 2010, which significantly strengthened MedDay's research capabilities as the company aims to expand its pipeline.

MedDay is well funded by investors including Sofinnova Partners, InnoBio, Andera Partners and Bpifrance Large Venture. MedDay is headquartered in Paris and has a team in Boston.

For more information, please see: www.medday-pharma.com. Follow us on Twitter: @MedDayPharm.

Contact information:
MedDay Pharmaceuticals
Email: contact@medday-pharma.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MedDay Pharmaceuticals S.A. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Bombardier Delivers First 90-seat Q400 Aircraft to SpiceJet21.9.2018 16:00Pressemelding

SpiceJet becomes the first airline to take advantage of the Q400 aircraft’s increased profit potential TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft today announced the delivery of its first 90-seat Q400 aircraft. The aircraft was handed over to India’s SpiceJet Limited (“SpiceJet”) the launch operator for the extra-capacity, 90-seat aircraft. “We are excited to induct the 90-seat Q400 aircraft into our fleet,” said Ajay Singh, Chairman and Managing Director, SpiceJet. “The additional seats and performance improvements will result in substantial reduction in unit costs and also we will enable us to address our market needs in the regional space.” “The delivery of the first 90-seat Q400 aircraft showcases the commitment of Bombardier’s Q Series turboprop program to respond to customer requirements as they address traffic growth in regional markets,” said Todd Young, Head of the Q Series Aircraft Program, Bombardier Commercial Aircraft. “I thank and congratul

Service Providers Speed Deployment, Reduce Costs with Patton Cloud Edge Orchestration Service20.9.2018 22:16Pressemelding

Now, Telecom and UCaaS service providers can easily provision, manage, monitor, secure, alert, troubleshoot, analyze, and optimize services on the customer premise GAITHERSBURG, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—US-manufacturer of UC, cloud, and IoT-enabling solutions for carrier, enterprise, and industrial networks—has launched the new Patton Cloud service for carriers and service providers that deliver All-IP and hybrid voice-and-data services to business subscribers. Patton Cloud delivers a low-cost, easy-to-use, web-based edge-orchestration service that delivers a superior user experience. It offers remote touchless provisioning, monitoring, and troubleshooting—as well as security and alerting tools that reduce service turn-up costs, trouble tickets, and subscriber attrition. The Patton Cloud service offers quality-control mechanisms including pro-active monitoring and troubleshooting—combined with feature-license distribution pools for managing value-added

Inspirata Promotes Top Executives to Expanded Roles in Digital Pathology20.9.2018 21:12Pressemelding

Inspirata Founder and Executive Vice President, Mark Lloyd, is taking on an expanded role overseeing product management, and Inspirata Senior Vice President, Andrew Chomos, has been appointed to General Manager, Digital Pathology, overseeing the Center of Excellence in Pittsburgh along with all North America sales and customer support efforts. Tampa, FL, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that two of its executives have taken on expanded roles in the company. The two are Inspirata Executive Vice President and Founder, Mark Lloyd, and Senior Vice President and General Manager, Digital Pathology, Andrew Chomos. Dr. Lloyd has accepted the expansion of his role to include product management for Digital Pathology. He is former cancer researcher at both Lombardi Cancer and Moffitt Cancer Center and is Inspirata’s foremost subject matter expert and thought leader on digital pathology and image

Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections20.9.2018 19:08Pressemelding

– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. “The European approval of XERAVA, right after our recently announced FDA approval, marks our second significant regulatory approval within one month

UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule20.9.2018 18:07Pressemelding

RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and the only animal model provider available on GSA Contract. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable research in the world and provide them with high quality sol

Digital Transformation is Not a One-Off — It’s About the Digital Journey20.9.2018 17:44Pressemelding

SoftServe study confirms four digital journey states with 71 percent of enterprises reporting early stages of adoption AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, today released the results of its market research study that examines how enterprises are responding to the digital economy. The research found that 71 percent of the respondents in the United States and the European Union are in the early stages—Reveal and Transform—of four unique states across the Enterprise Digital Journey. For an in-depth analysis and the full results, read The Enterprise Digital Journey white paper. With fierce competition in today’s global landscape, leveraging cutting-edge technology and deploying new business models is not a one-off pursuit, but rather a continuous process of iteration and refinement. Companies should stop referring to Digital Transformation and instead plan for a continuous Digital Journey. “The term Digital Transfo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom